Powder: -20°C for 3 years | In solvent: -80°C for 1 year
N-Acetyl-Ser-Asp-Lys-Pro 通过酶促处理胸腺素 β4 在骨髓细胞中形成。 它抑制多能造血干细胞进入细胞周期的 S 期,并防止小鼠中的 Ara-C 致死性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 487 | 现货 | ||
5 mg | ¥ 987 | 现货 | ||
10 mg | ¥ 1,670 | 现货 | ||
25 mg | ¥ 3,450 | 现货 | ||
50 mg | ¥ 4,910 | 现货 | ||
100 mg | ¥ 7,130 | 现货 |
产品描述 | Acetyl Ser-Asp-Lys-Pro is formed in bone marrow cells by enzymatic processing of thymosin β4. It inhibits the entry of pluripotent hemopoietic stem cells into S-phase of the cell cycle and protects against Ara-C lethality in mice. |
体外活性 | N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a specific substrate for the N-terminal site of ACE and increases 5-fold during ACE inhibitor therapy.??AcSDKP inhibited the proliferation of isolated cardiac fibroblasts (P<0.05) but significantly stimulated the proliferation of vascular smooth muscle cells.?Flow cytometry of rat cardiac fibroblasts treated with AcSDKP showed significant inhibition of the progression of cells from G0/G1 phase to S phase of the cell cycle.?In cardiac fibroblasts transfected with a Smad-sensitive luciferase reporter construct, AcSDKP decreased luciferase activity by 55+/-9.7% (P=0.01).?Moreover, phosphorylation and nuclear translocation of Smad2 was decreased in cardiac fibroblasts treated with AcSDKP.?To conclude, AcSDKP inhibits the growth of cardiac fibroblasts and also inhibits TGFbeta1-stimulated phosphorylation of Smad2.?Because AcSDKP increases substantially during ACE inhibitor therapy, this suggests a novel pathway independent of angiotensin II, by which ACE inhibitors can inhibit cardiac fibrosis. |
分子量 | 487.5 |
分子式 | C20H33N5O9 |
CAS No. | 127103-11-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0513 mL | 10.2564 mL | 20.5128 mL | 51.2821 mL |
5 mM | 0.4103 mL | 2.0513 mL | 4.1026 mL | 10.2564 mL | |
10 mM | 0.2051 mL | 1.0256 mL | 2.0513 mL | 5.1282 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
N-Acetyl-Ser-Asp-Lys-Pro 127103-11-1 Endocrinology/Hormones RAAS Ac-SDKP NAcetylSerAspLysPro Inhibitor inhibit N Acetyl Ser Asp Lys Pro Angiotensin-converting Enzyme (ACE) inhibitor